Cited by 1,059

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector

Szymczak, Andrea L, Workman, Creg J, Wang, Yao, Vignali, Kate M, Dilioglou, Smaroula, Vanin, Elio F, Vignali, Dario A A·2004·Nature Biotechnology

Abstract

Attempts to generate reliable and versatile vectors for gene therapy and biomedical research that express multiple genes have met with limited success. Here we used Picornavirus 'self-cleaving' 2A peptides, or 2A-like sequences from other viruses, to generate multicistronic retroviral vectors with efficient translation of four cistrons. Using the T-cell receptor:CD3 complex as a test system, we show that a single 2A peptide-linked retroviral vector can be used to generate all four CD3 proteins (CD3epsilon, gamma, delta, zeta), and restore T-cell development and function in CD3-deficient mice. We also show complete 2A peptide-mediated 'cleavage' and stoichiometric production of two fluorescent proteins using a fluorescence resonance energy transfer-based system in multiple cell types including blood, thymus, spleen, bone marrow and early stem cell progenitors.

Overview

Integrity signals

Registry

Crossref · 10.1038/nbt957

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 28

  1. Ryan, M.D. & Flint, M. Virus-encoded proteinases of the picornavirus super-group. J. Gen. Virol. 78, 699–723 (1997). · DOI
  2. Palmenberg, A.C. et al. Proteolytic processing of the cardioviral P2 region: primary 2A/2B cleavage in clone-derived precursors. Virology 190, 754–762 (1992). · DOI
  3. Donnelly, M.L. et al. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J. Gen. Virol. 82, 1027–1041 (2001). · DOI
  4. Ryan, M.D., King, A.M. & Thomas, G.P. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J. Gen. Virol. 72, 2727–2732 (1991). · DOI
  5. Donnelly, M.L. et al. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J. Gen. Virol. 82, 1013–1025 (2001). · DOI
  6. Klausner, R.D., Lippincott-Schwartz, J. & Bonifacino, J.S. The T cell antigen receptor: insights into organelle biology. Annu. Rev. Cell Biol. 6, 403–431 (1990). · DOI
  7. Persons, D.A. et al. Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Nat. Med. 4, 1201–1205 (1998). · DOI
  8. Vanin, E.F. et al. Development of high-titer retroviral producer cell lines by using Cre- mediated recombination. J. Virol. 71, 7820–7826 (1997). · DOI
  9. Julias, J.G., Hash, D. & Pathak, V.K. E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy. J. Virol. 69, 6839–6846 (1995). · DOI
  10. Liu, H.Y., Rhodes, M., Wiest, D.L. & Vignali, D.A.A. On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. Immunity 13, 665–675 (2000). · DOI
  11. Wang, B. et al. T lymphocyte development in the absence of CD3ε or CD3γδζε. J. Immunol. 162, 88–94 (1999). · DOI
  12. Love, P.E. et al. T cell development in mice that lack the zeta chain of the T cell antigen receptor complex. Science 261, 918–921 (1993). · DOI
  13. Chan, F.K. et al. Fluorescence resonance energy transfer analysis of cell surface receptor interactions and signaling using spectral variants of the green fluorescent protein. Cytometry 44, 361–368 (2001). · DOI
  14. de Felipe, P., Martin, V., Cortes, M.L., Ryan, M. & Izquierdo, M. Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Ther. 6, 198–208 (1999). · DOI
  15. Klump, H. et al. Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy. Gene Ther. 8, 811–817 (2001). · DOI
  16. Emerman, M. & Temin, H.M. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 39, 449–467 (1984). · DOI
  17. Wang, S., Beattie, G.M., Hayek, A. & Levine, F. Development of a VSV-G protein pseudotyped retroviral vector system expressing dominant oncogenes from a lacO-modified inducible LTR promoter. Gene 182, 145–150 (1996). · DOI
  18. Borman, A.M., Le Mercier, P., Girard, M. & Kean, K.M. Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res. 25, 925–932 (1997). · DOI · Paper page
  19. Sorrentino, B.P. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat. Rev. Cancer 2, 431–441 (2002). · DOI
  20. Pizzato, M. et al. Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. Gene Ther. 5, 1003–1007 (1998). · DOI
  21. Moriuchi, S. et al. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res. 58, 5731–5737 (1998).
  22. Kessels, H.W., Wolkers, M.C., van, D.B., van der Valk, M.A. & Schumacher, T.N. Immunotherapy through TCR gene transfer. Nat. Immunol. 2, 957–961 (2001). · DOI
  23. Zitvogel, L. et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum. Gene Ther. 5, 1493–1506 (1994). · DOI
  24. Vignali, D.A.A. & Vignali, K.M. Profound enhancement of T cell activation mediated by the interaction between the T cell receptor and the D3 domain of CD4. J. Immunol. 162, 1431–1439 (1999). · DOI
  25. Markowitz, D., Goff, S. & Bank, A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62, 1120–1124 (1988). · DOI
  26. Persons, D.A. et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 90, 1777–1786 (1997). · DOI
  27. Persons, D.A., Mehaffey, M.G., Kaleko, M., Nienhuis, A.W. & Vanin, E.F. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood Cells Mol. Dis. 24, 167–182 (1998). · DOI
  28. Carson, R.T., Vignali, K.M., Woodland, D.L. & Vignali, D.A. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Immunity 7, 387–399 (1997). · DOI

Cited by

Sorted by citations

See all 1,059

Metadata

Authors
Szymczak, A. L., Workman, C. J., Wang, Y., Vignali, K. M., Dilioglou, S., Vanin, E. F., & Vignali, D. A. A.
Venue
Nature Biotechnology
Published
2004-04-04
Volume
22
Issue
5
Pages
589-594
ISSN
  • 1087-0156
  • 1546-1696
Cited by
1,059
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review